[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

CytomX Reports Tomorrow With Analysts Already Looking Past August

CytomX Therapeutics (CTMX) reports second-quarter 2026 earnings tomorrow, August 6, after market close, with analysts expecting another quarterly loss as the clinical-stage biopharmaceutical company continues to burn cash while advancing its antibody-drug conjugate pipeline. The central question is whether CTMX can demonstrate meaningful progress in its Probody therapeutic platform and partnership revenues to justify its current valuation, or if mounting losses will continue to pressure the stock. With shares trading at $3.35 and down significantly from earlier highs, investors are looking for signs that the company's technology can translate into commercial success.

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing Probody...

Fundamentals

See More
  • Market Capitalization, $K 570,126
  • Shares Outstanding, K 170,187
  • Annual Sales, $ 76,200 K
  • Annual Income, $ -17,370 K
  • EBIT $ -65 M
  • EBITDA $ -65 M
  • 60-Month Beta 2.12
  • Price/Sales 7.41
  • Price/Cash Flow N/A
  • Price/Book 1.77

Options Overview Details

View History
  • Implied Volatility 101.16% (-3.22%)
  • Historical Volatility 50.85%
  • IV Percentile 32%
  • IV Rank 16.05%
  • IV High 329.23% on 03/10/26
  • IV Low 57.55% on 05/08/26
  • Expected Move (DTE 14) 0.55 (16.39%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 105
  • Volume Avg (30-Day) 576
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 26,953
  • Open Int (30-Day) 26,689
  • Expected Range 2.82 to 3.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.11
  • Number of Estimates 3
  • High Estimate $-0.09
  • Low Estimate $-0.13
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.01 +11.96%
on 08/03/26
4.02 -16.17%
on 07/10/26
-0.44 (-11.55%)
since 07/06/26
3-Month
2.82 +19.72%
on 06/09/26
4.23 -20.33%
on 05/08/26
-0.76 (-18.40%)
since 05/06/26
52-Week
1.72 +95.93%
on 08/14/25
8.21 -58.95%
on 03/16/26
+1.20 (+55.30%)
since 08/06/25

Most Recent Stories

More News
CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics: Q2 Earnings Snapshot

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027...

CTMX : 3.37 (+0.60%)
CytomX Reports Tomorrow With Analysts Already Looking Past August

Barchart Research What to Expect from CTMX Earnings CTMX Generated August 5, 2026 Current Price $3.35 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 25.62% CytomX Reports Tomorrow With Analysts...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY ® and Regeneron's Veloci-Bi ® platforms - - CytomX...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics to Present at Upcoming June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Q1 Earnings Call Highlights

CytomX Therapeutics (NASDAQ:CTMX) executives highlighted progress across the company’s lead clinical programs and reviewed first-quarter 2026 financial results, emphasizing continued development momentum...

CTMX : 3.37 (+0.60%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 3.53
2nd Resistance Point 3.46
1st Resistance Point 3.42
Last Price 3.37
1st Support Level 3.31
2nd Support Level 3.24
3rd Support Level 3.20

See More

52-Week High 8.21
Fibonacci 61.8% 5.73
Fibonacci 50% 4.97
Fibonacci 38.2% 4.20
Last Price 3.37
52-Week Low 1.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.